Dechra Acquires Gallant To Enter Veterinary Regenerative Medicine

Dechra has acquired Gallant Pet, a U.S. animal health biotechnology company developing ready-to-use mesenchymal stromal cell therapies for pets.

The completed transaction expands Dechra into regenerative medicine and adds a therapeutic platform intended to support multiple products across different conditions and animal species.

Dechra expects the first product from Gallant’s pipeline could become available as early as 2027, although development and regulatory outcomes remain uncertain.

Developing Off-The-Shelf Cell Therapies

Mesenchymal stromal cells are being studied for their ability to interact with biological processes involved in inflammation, tissue repair, and immune response.

Gallant is developing off-the-shelf therapies that would be prepared in advance rather than manufactured separately for each animal.

A ready-to-use approach could simplify storage, distribution, and administration compared with individually produced treatments.

The company aims to develop therapies for chronic and complex conditions in companion animals, including diseases for which current treatment options may focus primarily on symptom management.

Gallant’s platform is designed to support a pipeline rather than a single product. This creates opportunities to investigate additional diseases and species if the underlying technology demonstrates safety, effectiveness, manufacturing consistency, and regulatory compliance.

Combining Gallant Science With Dechra’s Commercial Reach

Dechra plans to combine Gallant’s cell-therapy research and manufacturing expertise with its global veterinary relationships, specialty-care portfolio, and commercialization capabilities.

The acquisition gives Gallant access to a larger animal health organization capable of supporting clinical development, regulatory work, manufacturing scale, and distribution.

For Dechra, the transaction adds a new therapeutic modality beyond conventional veterinary medicines.

Gallant CEO Dr. Linda Black emphasized that the two companies share a goal of making regenerative medicine more accessible to pets.

The companies did not disclose whether Gallant will retain its brand, which employees will transfer, or the specific indication planned for the first commercial product.

Any new therapy will remain subject to successful development and the regulatory requirements applicable in the markets where Dechra seeks approval.

KEY QUOTES:

This acquisition is a strategic investment in expanding what’s possible in veterinary care. By combining our specialty animal health expertise, global reach and established veterinary relationships with Gallant’s scientific innovation and regenerative medicine platform, we’re creating a strong foundation to bring new treatment options to veterinarians and their patients.

Dr. Cathy Knupp, Chief Scientific Officer of Dechra

Gallant was built on a bold idea that we could make regenerative medicine accessible for all pets in need. Dechra understood that vision from the start. We are thrilled to begin this new chapter as part of Dechra who shares our dedication to science and heart. I’m incredibly proud of the team that got us here, and excited to keep pioneering together.

Dr. Linda Black, CEO of Gallant